Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03682055 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
A Phase 1 study, sponsored by Cullinan Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03682055 is a Phase 1 study that was terminated before completion, run by Cullinan Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT03682055, a Phase 1 study, was terminated before completion, sponsored by Cullinan Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), as well as to evaluate the PK profile of VK-2019.
Interventions
- DRUG VK-2019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2020-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03682055
The ClinicalTrials.gov registry entry for NCT03682055 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cullinan Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VK-2019 is the first listed.
NCT03682055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03682055 about?
NCT03682055 is a clinical study titled "Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)". VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), as well as to evaluate the PK profile of VK-2019.
What is the current status of trial NCT03682055?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-04-04. Estimated completion is 2020-08-08.
What interventions are being tested in trial NCT03682055?
The interventions under investigation include: VK-2019 (DRUG).
Who is sponsoring clinical trial NCT03682055?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.